| |MARCH 20268ALEMBIC PHARMACEUTICALS RECEIVES FDA APPROVAL FOR EFINACONAZOLEGILEAD EXPANDS CANCER BET WITH $7.8B ARCELLX DEALGilead Sciences is set to acquire Arcellx in a deal worth up to $7.8 billion, strengthening its position in CAR-T therapy and deepening its push into cancer treatment.The acquisition, announced today, gives Gilead full control of Arcellx's lead cell therapy candidate, anito-cel, a treatment being developed for patients with relapsed or refractory multiple myeloma.Under the agreement, Gilead will pay $115 per share in cash to Arcellx shareholders. In addition, shareholders could receive an extra $5 per share if anito-cel achieves $6 billion in global net sales by 2029. The total transaction value, including the contingent payment, could reach $7.8 billion.The CAR-T therapy candidate anito-cel is currently under regulatory review, with a U.S. FDA decision expected in late 2026. If approved, the therapy could become a key growth driver for Gilead's oncology business. The company already partnered with Arcellx through its Kite unit, but this acquisition allows it to fully own and commercialize the product.Gilead said the deal is expected to close in the second quarter of 2026, subject to customary closing conditions. The move reflects the company's strategy to expand beyond its core HIV and liver disease portfolio and build a stronger presence in cancer therapies. POTOP STORIESAlembic Pharmaceuticals Limited has announced that it received final approval from the US Food & Drug Administration (FDA) for its efinaconazole topical solution, 10%.This approval marks a significant achievement for Alembic as the product is now therapeutically equivalent to the reference drug Jublia topical solution, 10%, from Bausch Health Americas, Inc.Efinaconazole topical solution is indicated for the treatment of onychomycosis of the toenail(s) caused by Trichophyton rubrum and Trichophyton mentagrophytes. With this approval, Alembic joins the ranks of key players in the pharmaceutical industry who are making strides in the dermatology space.Alembic was one of the first companies to submit an ANDA with a paragraph IV certification, a step that further emphasizes their commitment to delivering quality, affordable medications to patients. The market for efinaconazole topical solution is estimated to reach US$ 500 million by December 2025, according to IQVIA.This brings Alembic's total ANDA approvals to 234, including 215 final approvals and 19 tentative approvals from the US FDA. The company has demonstrated its consistent ability to bring competitive generics to market, benefiting both patients and healthcare systems worldwide. Headquartered in India, Alembic Pharmaceuticals has been a key player in the global pharmaceutical market since 1907, manufacturing and marketing generic pharmaceutical products worldwide. PO
< Page 7 | Page 9 >